Intracranial hemorrhage in patients with cancer treated with bevacizumab: The memorial Sloan-Kettering experience Journal Article


Authors: Khasraw, M.; Holodny, A.; Goldlust, S. A.; Deangelis, L. M.
Article Title: Intracranial hemorrhage in patients with cancer treated with bevacizumab: The memorial Sloan-Kettering experience
Abstract: Background: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor approved for recurrent glioblastoma (GBM), metastatic breast, colorectal and non-small-cell lung cancers (NSCLC). There has been a potentially increased risk of intracranial hemorrhage (ICH) in patients receiving bevacizumab. Methods: We retrospectively identified patients with ICH who received bevacizumab between 1 January 2001 and 10 January 2009. Results: We identified 1024 patients with ICH, 4191 patients who received bevacizumab and 12 (0.3%) who met both our criteria. There were eight women and four men with a median age of 66 years. Primary cancers were ovarian (n = 3), NSCLC (n = 3), colon (n = 1), angiosarcoma (n = 1) and GBM (n = 4). Intracranial tumors were present in 9 of the 12 patients; the remaining three (25%) had no evidence of intracranial pathology. Two hundred and fifty-seven patients with these same primary pathologies and brain tumors were treated with bevacizumab; ICH was seen in nine (3.7%), which was comparable to the 3.6% frequency seen in comparable patients not receiving bevacizumab. Conclusions: ICH with bevacizumab treatment in this population is rare and does not appear to increase its frequency over the baseline rate of ICH in a comparable population. Most bevacizumab-related ICH occurs into central nervous system tumors but spontaneous hemorrhages were seen. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Keywords: controlled study; aged; major clinical study; bevacizumab; cancer patient; brain radiation; brain tumor; ovary cancer; lung non small cell cancer; incidence; deep vein thrombosis; angiosarcoma; retrospective study; risk assessment; colon cancer; glioblastoma; vascular endothelial growth factor; brain metastasis; brain hemorrhage; low molecular weight heparin; intracranial hemorrhage; primary brain tumors; metastatic brain tumors
Journal Title: Annals of Oncology
Volume: 23
Issue: 2
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2012-01-01
Start Page: 458
End Page: 463
Language: English
DOI: 10.1093/annonc/mdr148
PROVIDER: scopus
PUBMED: 21543627
DOI/URL:
Notes: --- - "Export Date: 1 March 2012" - "CODEN: ANONE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrei Holodny
    207 Holodny
  2. Mustafa Khasraw
    10 Khasraw